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Abstract: 
Background: Oncogenic activation of the epidermal growth factor receptor (EGFR) signaling 
pathway occurs in a variety tumour types, albeit in human melanoma the contribution of 
EGFR is still unclear. 
Methods: The potential role of EGFR was analyzed in four BRAF-mutant, one NRAS-mutant 
and one wild-type NRAS-BRAF-carrying human melanoma cell lines. We have tested 
clinically available reversible tyrosine kinase inhibitors (TKI) gefitinib and erlotinib, 
irreversible EGFR-TKI pelitinib and a reversible experimental compound (PD153035) on in 
vitro proliferation, apoptosis, migration as well as in vivo metastatic colonization in a spleen-
liver model. 
Results: The presence of the intracellular domain of EGFR protein and its constitutive activity 
were demonstrated in all cell lines. We detected significant differences between the efficacies 
of EGFR-TKIs, irreversible inhibition had the strongest anti-tumour potential. Compared to 
BRAF-mutant cells, wild-type BRAF associated with relative resistance against gefitinib. In 
combination with gefitinib, selective mutant BRAF-inhibitor vemurafenib showed additive 
effect in BRAF-mutant cell lines. Treatment of BRAF-mutant cells with gefinib- or pelitinib 
attenuated in vitro cell migration and in vivo colonization. 
Conclusions: Our preclinical data suggest that EGFR is a potential target in the therapy of 
BRAF-mutant malignant melanoma; however, more benefits could be expected from 
irreversible EGFR-TKIs and combined treatment settings. 
 
Keywords:  
EGFR; small molecule tyrosine kinase inhibitors; human malignant melanoma; metastasis; 
xenograft 
 
Article type:  
Original research article 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
BACKGROUND 
Malignant melanoma is an aggressive type of malignant skin lesions with worldwide 
increasing incidence [1], which is resistant to common cytotoxic therapies. Since malignant 
melanomas have a potential to form organ metastases in a very early phase of primary growth, 
a better understanding of their progression is urgently needed. In the past few years paradigm 
shift occurred in the treatment modalities: in contrast to the previous practice when major 
survival benefit could only be achieved with early detection and complete surgical removal, 
recently target based modalities have appeared on the horizon. Fifty to sixty percent of 
malignant melanomas carry mutation in the BRAF oncogene, vemurafenib and dabrafenib 
show activity against the V600E-mutant BRAF [2, 3]. Nevertheless, application of BRAF-
inhibitors can induce cutaneous squamous cell carcinoma due to paradoxical activation of 
RAF signaling in cells carrying wild type BRAF [4]. Moreover, a number of BRAF mutant 
melanomas show limited response due to intrinsic resistance and initially responding patients 
often relapse because of acquired resistance [5]. To prevent these mechanism novel 
combinations are in development, recently clinical trials proved that the addition of MEK-
inhibitors to V600E-selective BRAF-inhibitors was associated to significant improvement in 
progression-free survival among patients of BRAF-mutated metastatic melanoma [6, 7]. 
Hyperactivation of the epidermal growth factor receptor (EGFR) signaling components 
commonly presents in human melanoma (e.g. NRAS-BRAF-MAPK, PI3K-AKT), which 
suggests the potential role of EGFR itself as well. EGFR (Her-1 or c-erbB-1), a member of 
the c-erbB receptor tyrosine kinase family, is a glycoprotein (170 kDa) composed of an 
extracellular binding domain, transmembrane lipophilic segment, and an intracellular protein 
tyrosine kinase domain with a regulatory carboxyl terminal segment. EGFR becomes 
activated by homodimerization, a mechanism that could be promoted by ligand binding as 
well as by high receptor density due to overexpression [8]. Receptor activation normally leads 
to the recruitment and phosphorylation of several intracellular substrates, regulating various 
cellular activities such as differentiation, increased proliferation, survival and migration [9]. 
Aberrant activation of EGFR has been shown to correlate with poor prognosis in a wild range 
of malignant tumors, e.g. urinary bladder, cervix, esophagus, ovarian cancers, and tumors of 
the head and neck region [10]. Therapeutic inhibition of tyrosine kinase activity by small 
molecule substrates is a possible approach to interfere with such an aberrant activation of TK-
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type receptors: small molecule tyrosine kinase inhibitors (TKIs) bind to the ATP cleft of the 
TK receptor and selectively block growth factor-stimulated signal activation via dimerization 
and autophosphorylation [11]. Inhibition of phosphorylation leads to depletion of the 
activated downstream effectors, resulting in attenuation of tumor progression. 
Previously a number of experimental studies suggested the importance of EGFR function in 
malignant melanoma cells [12-16]. Furthermore, according to clinicopathological data, EGFR 
gene copy number alterations in primary cutaneous malignant melanomas were associated 
with poor prognosis [17]. Several genomic and proteomic analysis confirmed the potential 
role of EGFR in the progression of malignant melanoma [18-20], therefore EGFR-TKI 
strategy could serve as a potential anti-melanoma approach. Recent studies demonstrated in 
BRAF-mutant colorectal cells that selective inhibition led to feedback activation of EGFR 
[21]. Previous findings confirmed a similar mechanism in the development of adaptive 
resistance to vemurafenib in the case of BRAF-mutant malignant melanoma as well [22], 
therefore simultaneous application of BRAF and EGFR inhibitors could be a potential novel 
combination. 
In our preclinical study, we first examined the EGFR-TK-status at protein level in six human 
melanoma cell lines representing the major oncogenic driver mutations (mutant BRAF, 
mutant NRAS, double wild-type cells). Moreover, we studied the potential effect of specific 
EGFR TKIs in combination with vemurafenib on proliferation, apoptosis and migration of 
human melanoma cells in vitro as well as on in vivo growth and colonization of human 
melanoma xenografts. 
 
METHODS 
Cell lines and culture conditions  
BRAF-mutant A2058 cell line was provided by L. A. Liotta (NCI, Bethesda, MD), HT168-
M1 human melanoma was the derivative of A2048 with high metastatic potential [23], HT199 
melanoma line was established by our group [24], WM983B melanoma cell lines were gifts 
from M. Herlyn (Wistar Institute, Philadelphia, PA). NRAS-mutant M24met melanoma line 
was kindly provided by B. M. Mueller (Scripps Research Institute, La Jolla, CA). Double 
wild-type MEWO and A431 squamous carcinoma cells (which served as a positive control for 
EGFR) are available from ATCC. Human melanoma cell lines were grown in medium RPMI-
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1640, while A431 were cultured in DMEM containing 4500 mg/l glucose (Sigma Chemical 
Co., St. Louis, MO), both were supplemented with 5% fetal bovine serum (Sigma) and 1% 
penicillin-streptomycin (Sigma), at 37°C in a humidified atmosphere of 5% CO2. 
 
Flow cytometric measurement of EGFR protein expression 
Cells from monolayer cultures were detached with 0.02% EDTA (Sigma), then washed with 
phosphate-buffer-saline (PBS) for 3x5 min, fixed and permeabilized by methanol for 15 min. 
After blocking nonspecific binding sites with 3% BSA for 15 min, cells were labelled for 45 
min at 37 ºC with a mouse monoclonal antibody against the intracellular amino acid region of 
EGFR between 1020 and 1046, purchased from Becton-Dickinson (Sunnyvale, CA, 1:20 in 
PBS). After washing period RPE-conjugated goat polyclonal anti-mouse antibody 
(DakoCytomation, Glostrup, Denmark) was applied for 45 min at 37 ºC. Fluorescence was 
analyzed by flow cytometer (CyFlow SL-Green, Partec, Munster, Germany) using FlowMax 
software (Partec). Positive events from a total of 104 cells were counted. Negative controls 
were prepared by primary antibody with isotype-matched nonimmune IgG (Sigma). 
 
Small molecule tyrosine kinase inhibitors 
EGFR-specific TKI gefitinib (ZD1839, Iressa®; [N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-
(3-morpholin-4-ylpropoxy)quinazolin-4-amine]) was kind gift of AstraZeneca. Erlotinib 
(OSI-774, Tarceva®; [N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine]) 
and irreversible inhibitor pelitinib (EKB-569; [N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-
7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide]) were synthesized by Vichem 
Chemie Ltd., Budapest, Hungary. PD153035 [4-[(3-bromophenyl)amino]-6,7-
dimethoxyquinazoline] were purchased from Calbiochem (La Jolla, CA, USA). V600E-
selective BRAF-inhibor vemurafenib (PLX4032, [N-(3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-
b]pyridin-3-yl]carbonyl-2,4-difluorophenyl)propane-1-sulfonamide] was provided by Selleck 
Chemicals (Munich, Germany). All TKIs were suspended in DMSO (Sigma) and used at 
0.01-100 μM concentrations in 0.5% DMSO-medium for in vitro studies. For in vivo 
metastasis assays vaporized inhibitors were suspended in Tween-20 and diluted in physiologic 
saline to reach a final concentration of 1%. The final applied doses of gefitinib, pelitinib and 
vemurafenib were 2 mg/kg and 20 mg/kg, 0.04 mg/kg and 0.4 mg/kg, 12.5 mg/kg and 25 
mg/kg, respectively. (Applied in vivo doses were based on in vitro proliferation assays.) 
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Immunofluorescence  
Melanoma cells of monolayer culture were fixed in paraformaldehyde for 10 min and then 
permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 1 min. After washing in PBS for 
3x5 min and blocking with 1% bovine serum albumine (BSA; Sigma) and goat serum (9:1) 
for 30 min at room temperature, slides were incubated with primary phosphospecific rabbit 
anti-EGFR[pY1068] antibody (Biosource, Nivelles, Belgium, 1:20 in PBS) for 45 min at 37°C. 
After washing, biotin-conjugated anti-rabbit IgG (Amersham, Buckinghamshire, UK) was 
applied for 40 min at 37°C (dilution 1:100). EGFR protein was visualized by streptavidin-
FITC (dilution 1:100, Vector Laboratories, Burlingame, CA). Negative controls were 
prepared by primary antibody with isotype-matched non-immune IgG (Sigma). Cell nuclei 
were stained with propidium iodide (PI, Sigma). Slides were covered with Vectashield 
(Vector Laboratories) and examined with confocal microscopy (Eclipse C1 Plus, Nikon 
Optoteam, Vienna, Austria). 
 
Kinexus Kinex KinetworksTM protein kinase screen 
WM983B control and treated cells with 25 µM gefitinib for 5 min or 30 min were prepared 
according to the recommendations of Kinexus Bioinformatics Corporation (Vancouver, BC, 
Canada; www.kinexus.ca). 1x107 adherent cells were washed twice with PBS, and 200 μl ice-
cold lysis buffer was added to each sample (20 mM MOPS, pH 7.0; 2 mM EGTA; 5 mM 
EDTA; 30 mM sodium fluoride; 60 mM β-glycerophosphate, pH 7.2; 20 mM sodium 
pyrophosphate; 1 mM sodium orthovanadate; 1% Nonidet P-40; 1 mM 
phenylmethylsulfonylfluoride; 3 mM benzamidine; 5 μM pepstatin; 10 μM leupeptin; 1 mM 
dithiothreitol; final pH of the homogenizing buffer was adjusted to 7.2). Scrapped cells were 
collected, sonicated four times for 10 seconds each time with 10-15 second intervals on ice, 
each homogenates were centrifuged at 90,000 x g 30 min at 4°C in ultracentrifuge. 
Supernatants were transferred to 1.5 ml microcentrifuge tubes, resuspended in SDS-PAGE 
Sample Buffer (31.25 mM Tris-HCl, pH=6.8; 1% SDS; 12.5% glycerol; 0.02% bromophenol 
blue; 1.25 % β-mercaptoethanol) to final protein concentration of 1.4 mg/ml, and shipped to 
Kinexus. Commercially available service of fluorescent labelling, hybridization onto KPCS-
1.0 microarray with selected phospospecific antibodies (ERK1/2, MEK1/2, p38 MAPK), as 
well as scanning, imaging and quantitative analysis of the enhanced chemiluminescence 
signal of the detected proteins in the EGFR-pathway were performed by Kinexus. Images of 
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immunoblots were provided by Kinexus, and our further conclusions were based on their 
evaluations. 
 
Flow cytometric measurement of apoptosis 
Melanoma cells of monolayer were previously treated for 48 hours with different 
concentrations EGFR-TKIs and/or vemurafenib, detached with EDTA, washed with PBS, 
then fixed with 70% ethanol (30 min, 4°C). Samples were washed twice with PBS and 
incubated with propidium-iodide and RNAse (CyStain PI Absolute T, Partec) for 4 hours at 
room temperature. The amount of DNA in cells was measured by flow cytometer (CyFlow, 
Partec), and the percentage of the apoptotic cells (sub-G1 fraction) was analyzed by FlowMax 
software. 
 
Cell proliferation assay 
Cell suspensions containing 5x104 viable cells/ml were plated in 96-well dishes (Greiner, 
Frickenhausen, Germany), incubated for 24 hours and treated with gefitinib, PD153035, 
erlotinib, pelitinib at concentrations of 0.1-100 μM and/or 5 μM of PLX4032 in 200 μl serum-
free or serum-containing medium for 48 hours. At the end of incubation, cell monolayers 
were fixed with 10% trichloroacetic acid and stained for 15 min with Sulforhodamine B 
(SRB). Wells were repeatedly washed with 1% acetic acid to remove excess dye. Protein-
bound dye was dissolved in 10 mM Tris, and absorbance was measured at 570 nm using 
microplate reader (BioRad, Hercules, CA). 50% inhibitory concentrations (IC50) were 
calculated by Dose-Effect Analysis with Microcomputers software (Elsevier-Biosoft, 
Cambridge, UK). 
 
Modified Boyden-chamber migration assay 
Cell migration was assayed by a method reported previously [25]. Human melanoma cells 
were previously treated with different concentrations of gefitinib, pelitinib or vemurafenib for 
24 hours at 37C, harvested with 0.02% EDTA, washed twice with serum-free medium, and 
resuspended at a density of 106 viable cells/ml in medium contained 0.1% BSA.  Viability was 
assayed by trypan blue staining (Sigma). 20 μl of the cell suspension was placed on top of the 
96-well CXF8 plates (polycarbonate filter with 8 μm pore size, Neuroprobe Inc., Cabin John, 
MD) and the lower compartment was filled with 30 μl of fibronectin in RPMI (100 μg/ml, 
Sigma). Cells were allowed to migrate for 6 hours (except M24met, where 24 hour incubation 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
period was applied) at 37 ºC in a humidified atmosphere of 5% CO2. The cells on the upper 
surface of the filter were then removed mechanically and the membranes were stained with 
toluidine blue (Sigma). Six independent parallel samples were applied. Migrated cells were 
counted under a light microscope in 3 high-power fields per sample. 
 
Animal experiments for liver colonization 
SCID mice (C.B-17/lcr-Prkdcscid/lcrlcoCrl) were bred and maintained in our specific 
pathogen-free colony and housed 10 to a cage. WM983B and HT168-M1 human melanoma 
cells from monolayer culture were detached, washed with serum-free medium and one-cell 
suspension was inoculated into the spleen of SCID mice with a number of 106 or 5x104 
cells/animal, respectively. Fourteen days after intrasplenic injection animals were randomized 
(10 animals per group) and treated intraperitoneally daily for 21 days. Reversible EGFR-
specific tyrosine kinase inhibitor gefitinib, irreversible pelitinib and V600E-selective BRAF-
inhibitor vemurafenib were suspended in physiologic saline containing 1% Tween-20. After 
termination the weight of the primary tumors was measured. Livers were fixed in 10% neutral 
buffered formalin for 48 hours and the number of liver colonies was counted under a 
stereomicroscope. 
 
Ethics approval 
All animal experiments were conducted following standards and procedures approved by the 
Animal Care and Use Committee of the National Institute of Oncology, Budapest (license 
number: 22.1/722/3/2010). 
 
Immunohistochemistry 
Routinely fixed xenograft tumors were dehydrated in a graded series of ethanol, infiltrated 
with xylene and embedded into paraffin at a temperature not exceeding 60°C. Three to four 
micron thick sections were mounted on Superfrost slides (Thermo Shandon, Runcorn, UK) 
and were manually deparaffinized. Endogenous peroxidase activity was blocked by 3% H2O2 
in methanol for 5 min at room temperature. Slides were immersed in 0.05 mM citrate buffer 
(pH=9) and exposed to 93°C for 10 min (MFX-800-3 automatic microwave, Meditest, 
Budapest, Hungary). 
Slides were primarily treated with rabbit antibody (in dilution 1:100) against phospho-S6 
ribosomal protein (pS6; Cell Signaling, Danvers, MA) and incubated overnight at 4°C. After 
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washing, secondary antibody Biotinylated Link (Dako) was used and incubated for 10 
minutes at room temperature. For visualization a standard avidin-biotin peroxidase technique 
(ABC system, Dako) was used with aminoethyl carbazole as chromogen. 
 
Statistical analysis 
To determine statistical differences between different strata ANOVA (analyses of variance) 
were used with the post hoc Scheffé-test where parametric methods were available. For the 
animal experiments we used non-parametric Kruskal-Wallis test with post hoc analysis. 
Statistical significance was determined when P values were under 0.05. Statistical analysis 
was performed by Statistica 11.0 software (StatSoft, Tulsa, OK). 
 
RESULTS 
EGFR-signalization in human melanoma cells 
Fixed and permeabilized cells were labeled with antibodies specific for the intracellular 
domain of the EGF receptor, and the ratio of positive cells was evaluated by flow cytometry. 
Expression of EGFR detected by antibody against the intracellular domain showed 52-88% 
positivity in the studied human melanoma cell lines (Fig. 1). 
In our previously published work we demonstrated tyrosine kinase activation and inactivation 
by immunofluorescence microscopy using a phosphospecific antibody [26]. By the 
application of EGFR-pY1068-specific antibody we detected constitutively phosphorylation of 
EGFR without exogenous EGF stimulation in HT168-M1 and WM983B human melanoma 
cell lines (Fig. 2A, C). Furthermore, the EGFR signal could be inhibited by the EGFR-
specific TKI, gefitinib (Fig. 2B, D). 
Kinexus Kinex KinetworksTM phosphoprotein assay confirmed that EGFR-specific inhibition 
by gefitinib affected elements of the EGFR-pathway in WM983B cells: activation of MEK1/2 
and Erk1 were blocked at both endpoints, while Erk2 and p38a MAPK were blocked at 5 min, 
albeit the inhibitory effect was weakened at 30 min (Fig. 2E-F). Of note, that although p38a 
MAPK is involved in the EGFR signaling via RAC1, the major inducing stimuli are hypoxia 
and stress [27]. 
 
Effect of EGFR-TKIs on the in vitro proliferation of human melanoma cells 
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The inhibitory potential of gefitinib on the phosphorylation of EGFR suggested that EGFR-
TKIs may have an effect on malignant melanoma at cellular level (Fig. 2). The inhibition of 
EGFR significantly decreased in vitro proliferative capacity of the human melanoma cells in 
serum-free and serum-containing media (Table 1A and B). The most potent inhibitor was 
irreversible EGFR-TKI pelitinib (IC50 values were in the range of 0.27-2.16 μM). In the case 
of gefitinib, IC50 values were between 0.25-17.2 μM; wild-type EGFR receptor expressing 
NRAS-mutant M24met cell line the [12] and double wild-type MEWO showed relative 
resistance to such inhibitor treatment. In BRAF-mutant lines the effect of PD153035 was 
relatively weaker compared to that of gefitinib, while M24met and MEWO showed total 
resistance. Regardless of oncogenic mutation status, all studied human melanoma cell lines 
were resistant to erlotinib, while the proliferation of the reference non-melanoma cell line, 
A431 was inhibited successfully. Generally IC50 values of human melanoma cells were 
higher than that of EGFR-amplified A431 human squamous cell line. Furthermore, in BRAF-
mutant melanoma cells vemurafenib enhanced the inhibitory effect of gefitinib, while it 
proved to be ineffective in wild-type BRAF-carrying cells, which property was more 
significant in serum-containing media (Table 1A and B). 
 
Apoptosis induction by EGFR-TKIs in human melanoma cell lines 
To investigate the effect of EGFR inactivation on cell survival/apoptosis, we treated human 
melanoma cells with small molecule TKIs for 48 hours, and after propidium-iodide staining, 
samples were analyzed by flow cytometry. Since erlotinib proved to be ineffective to interfere 
with cell viability, we have not tested its potential for apoptosis induction. Measurement of 
sub-G1 fractions (Fig. 3) revealed that significant induction of apoptosis have not occurred in 
the range of the IC50 values for proliferation inhibition in most of the studied cell lines. After 
treatment with higher concentrations of gefitinib (25 and 50 μM) a strong, dose-dependent 
induction of apoptosis was shown in BRAF-mutant melanoma cells (Fig. 3A). Irreversible 
inhibitor pelitinib was already effective at lower concentrations, 5 μM led to 23-30% of sub-
G1 fraction (Fig. 3B). PD153035 showed the weakest pro-apoptotic effect (Fig. 3C). 
Similarly to the proliferation assay, all the three reversible EGFR-TKIs were less capable to 
induce intense apoptosis in the wild-type BRAF-expressing M24met and MEWO cell lines; 
however the irreversible inhibitor pelitinib showed higher activity. Of note that vemurafenib 
have not induced significant apoptosis, its inhibitory effect was rather realized through the 
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blockade of cell cycle in G1-phase, and furthermore this effect was detectable only in BRAF-
mutant cell lines (data not shown). 
 
Effects of EGFR-TKIs on the in vitro migration of human melanoma cells 
To investigate the effect of gefitinib and pelitinib on cell migration, we used modified 
Boyden-chamber assay using fibronectin as chemoattractant. Similarly to vemurafenib, pre-
treatment with the EGFR-specific TKIs significantly reduced 6 hour migration of the BRAF-
mutant human melanoma cells (Fig. 4). The inhibitory capacity of gefitinib and pelitinib 
proved to be dose-dependent. Pre-treatment with 10 μM concentration of pelitinib completely 
abolished viability of HT168-M1 cells, therefore migration assay could not be performed. 
 
EGFR-TKI strategy inhibited liver colonization of BRAF-mutant WM983B and HT168-
M1 xenografts 
Based on our in vitro results, we examined the in vivo effect of gefitinib in combination with 
vemurafenib and pelitinib alone on the liver colonization of WM983B and HT168-M1 human 
melanoma cells in SCID-mice. Fourteen days after intrasplenic inoculation of WM983B or 
HT168-M1 cells, mice were treated intraperitoneally with gefitinib or pelitinib daily for three 
weeks, at doses of 2 mg/kg, 20 mg/kg or 0.04 mg/kg, 0.4 mg/kg, respectively. Based on the in 
vitro IC50 values, we applied equivalent in vivo dose, 2 mg/kg of gefitinib or 0.4 mg/kg of 
pelitinib, and we administered 10-fold higher or lower concentrations, respectively. 
Vemurafenib was applied at clinically relevant doses (12,5 mg/kg or 25 mg/kg). The weight 
of the primary tumors was measured during the autopsy and the number of liver colonies was 
determined under stereomicroscope after formaldehyde-fixation. Contrary to the in vitro 
results in the case of HT168-M1 cells, gefitinib did not inhibit primary tumor and liver 
colonization (data not shown) as compared to the irreversible inhibitor pelitinib, which 
reduced liver colonies at a dose of 0.4 mg/kg (Fig. 5A). In the case of the other BRAF-mutant 
WM983B melanoma cells, gefitinib significantly (p<0.05) inhibited liver colonization at the 
dose of 2 mg/kg as well as 20 mg/kg in a dose-dependent manner (Fig. 5B). Compared to 
control group, vemurafenib significantly affected liver colonization, however additive effect 
of the combination did not reach significance, only a statistical trend appeared. In the TKI-
treated groups primary tumor sizes did not differ significantly from that of solvent-treated 
control, however a tendency of decrease was observed: 18% and 27% in the case of 2 mg/kg 
and 20 mg/kg of gefitinib and 9% and 14% in the case of 0.04 mg/kg, 0.4 mg/kg of pelitinib, 
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respectively. Interestingly, vemurafenib have not shown any effect on primary tumors either 
alone or in combination (data not shown). 
Ribosomal S6 protein is the part of the translational machinery, one of the effectors of 
EGFR/KRAS/MAPK-pathway, therefore its phosphorylation status is highly dependent of 
signalization activity. By immunohistochemical examination of the primary WM983B 
xenograft tumors we confirmed in vivo inhibitory effect of gefitinib, since compared to 
solvent control, gefitinib-treated cells showed lower pS6-positivity (Fig 5C-D). 
 
DISCUSSION 
Aberrant activation of the tyrosine kinase EGFR was demonstrated in several common solid 
tumors, resulting in increased proliferation, survival, invasiveness and metastasis. Constitutive 
activity of EGFR has been shown to correlate with poor prognosis in urinary bladder, 
cervical, esophageal, ovarian cancers and head and neck tumors [10]. EGFR-inhibitory 
strategy has already been approved in cancers of the head and neck region, colon cancers and 
non-small cell lung cancer [28]. Nevertheless, the effectiveness of EGFR inhibition may be 
influenced by oncogenic mutations in the downstream signaling pathway, for instance by the 
V600E mutant BRAF or by mutant NRAS, which are the two most common driver mutations 
in malignant melanoma cases [29]. On the other hand, activation of EGFR and vemurafenib 
resistance linked to the signal of microphthalmia-associated transcription factor [30]. 
Although EGFR-family pathway has more influent on epidermal tissue and cancers, it was 
previously described that heregulin (ligand of ErbB3 and ErbB4 receptors) stimulated the 
proliferation of both melanocytes and malignant melanoma cells [13]. Since heregulin 
contains similar domains to EGF, the oncogenic effect of EGFR (ErbB1) could not be 
excluded in malignant tumor type that shares neuroectodermal origin, malignant melanoma or 
glioblastoma multiforme. In the latter the role of EGFR seems to be more clear [31]. Among 
numerous other tyrosine kinases Tworkoski et al. showed the activity of EGFR in human 
malignant melanoma cell lines [20]. A previous work using standardized ATP-based 
chemosensitivity assay showed significant response of human melanoma cells to gefitinib, 
however, the extracellular domain of EGFR could be detected only in minority of tumor 
samples [14]. These findings are in concordance with our results that all the studied human 
melanoma cell lines expressed the intracellular domain of the receptor that harbours the 
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tyrosine kinase domain. In mutant BRAF-carrying melanoma cell lines EGFR-TKI treatment 
led to significant response in the signaling cascade, inhibited phosphorylation level of EGFR 
itself which resulted inactivation of the major elements in the downstream signal (e.g. 
MEK1/2, Erk1/2, p38a MAPK) in 30 minutes. These short-term alterations in the EGFR-
signal may be the explanation of the detected long-term biological responses. Furthermore, 
we are the first to categorize the effectiveness of EGFR-TKIs in human melanoma according 
to the molecular pattern: treatment blocked proliferation activity of BRAF-mutant cells, 
however wild-type BRAF-carrying human melanoma cells showed relative insensitivity 
against gefitinib. 
Inhibition of EGFR leads to the inactivation of PI3K/Akt survival signal, which results in 
increased apoptosis [32-34]. Our results confirmed previous studies showing that albeit a 
minority of malignant melanoma cells expresses extracellular domain of EGFR, gefitinib still 
proved to be an apoptosis-inducing agent [15, 35]. This observation suggests the involvement 
of intracellular domain in the survival signal, while the presence of the extracellular region is 
not essential. Another novel statement of our current work is that irreversible inhibition of 
EGFR by pelitinib had a more potent effect on apoptosis as well as on proliferation than the 
already clinical administered agents. Previously Djerf Severinsson et al. showed that pan-
ErbB tyrosine kinase inhibitor canertinib also had better anti-tumor activity in malignant 
melanoma [36]. Additionally, our results served the first evidence that irreversible inhibition 
could work in NRAS-BRAF double wild-type as well as NRAS-mutant melanoma cells. 
The relative resistance of NRAS-mutant M24met cell line to gefitinib could be explained by 
previous observations that confirmed the inactivity of EGFR in those cells [12], and the 
receptor was not capable to react to exogenous EGF stimulation despite the gene was 
amplified [17]. Probably the relative resistance of double wild-type MEWO cells is caused by 
EGFR-independent signalization, since this line is NF1 mutant, which resulted loss of NRAS-
suppression [37]. In our present study we have not only confirmed the experimental work of 
Djerf et al. [35], but according to the driver oncogenic mutation status we have systematically 
explored the potential of EGFR-TKI strategy in malignant melanoma. Moreover, based on 
previous theories in colorectal cancer that selective BRAF(V600E) inhibition led to feedback 
activation of EGFR [21], we have first shown that the efficacy of EGFR-TKIs can be 
enhanced by vemurafenib. 
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EGFR not only plays a role in the regulation of proliferation and survival but in cell migration 
as well. Selective EGFR-TKI treatment resulted in inhibition of adhesion, migration and 
invasion in several tumor cell lines, such as cutaneous squamous cell carcinoma, carcinoma of 
the head and neck region, malignant mesothelioma, hepatocellular carcinoma and prostate 
cancer [38-43]. Moreover, numerous data of animal experiments is available that gefitinib had 
an in vivo inhibitory effect of metastasis formation in mice using hepatocellular carcinoma, 
head and neck cancer, squamous cell carcinoma of the vulva and prostate carcinoma cells [44-
48]. We are the first to show that in BRAF-mutant melanoma cells selective inhibition of 
EGFR prevented both in vitro motility and in vivo metastasis formation, and that the 
irreversible inhibitor pelitinib could open a new option for those cells which showed relative 
resistance against the reversible inhibitor gefitinib (e.g. NRAS-mutant, NRAS-BRAF double 
wild-type cells). At the same time, in contrast to previous findings, our vemurafenib-treatment 
has not impacted migratory activity of human melanoma cells [49], which effect was 
irrespective of BRAF and NRAS status; however, we applied other cell lines and shorter 
incubation period than the cited work. 
Genetic analysis of tumors of vemurafenib-relapsed melanoma patients revealed several 
acquired resistance mechanisms. These includes among others overexpression of previously 
overseen growth factor pathways of melanoma involving EGFR [22], EGFR3 [50], 
EGFR2/HER2, AXL and PDGFR receptors [51]. Studies revealed also acquired genetic 
alterations such as ERBB4, besides FLT1, PTPRD, RET, TERT and RUNX1T1 [51]. These 
data all conclude to the same direction that in human melanoma cells inhibition mutant BRAF 
frequently results in the (re)-activation of the EGFR receptor family signaling pathway. 
Moreover, recent clinical trials confirmed that in combination downstream elements of the 
TK-signal should be feasible targets: MEK-inhibitors improved the antitumor effect of mutant 
BRAF-specific inhibitors [6, 7]. Our data suggests that these pathways are already active in 
mutant BRAF-expressing human melanoma cells and themselves serve targets for therapeutic 
interventions which can further be exploited later upon vemurafenib resistance. A phase II 
study of gefitinib showed minimal clinical efficacy as a single-agent in unselected patients 
with metastatic melanoma [51], which can be explained by the different EGFR activities in 
various molecular subgroups of human melanoma. Beside of others our data also suggests 
revisiting the clinical application of EGFR-TKIs, since several new agents are now available. 
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CONCLUSIONS 
In summary, our study suggests that EGFR is a potential target in the therapy of BRAF-
mutant malignant melanoma; however, more benefits could be expected from irreversible 
EGFR-TKIs and combined treatment settings. 
 
LIST OF ABBREVIATIONS: 
ATP: adenosine triphosphate 
DNA: deoxyribonucleic acid 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
FCS: fetal calf serum 
GTP: guanosine triphosphate 
Ras: protein product of RAS gene 
RAS: rat sarcoma gene 
RNAse: ribonuclease 
SD: standard deviation 
TKI: tyrosine kinase inhibitor 
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TITLES AND LEGENDS TO FIGURES 
Fig. 1. Expression of the intracellular domain of EGFR protein in human melanoma cell 
lines (flow cytometry, 3 parallel samples, data are mean ± SD). 
Fig. 2. Gefitinib inhibited the activity of EGFR-signal in HT168-M1 and WM983B 
human melanoma cells. Immunofluorescent detection of p-EGFR (green) using antibody 
against pY1068, nuclei were labeled by PI (red) (A-D). Commercially available Western-blot 
analysis of Kinexus Kinex KinetworksTM demonstrated the effect of gefitinib on WM983B 
cells, bands represent ERK1/2, MEK1/2 and p38a MAPK – marked by white lines (E). The 
analysis of Kinexus Kinex KinetworksTM protein kinase assay confirmed that EGFR-specific 
inhibition blocked activation of MEK1/2 and Erk1 at both endpoints, while Erk2 and p38a 
MAPK were blocked at 5 min, albeit the inhibitory effect was weakened at 30 min (F). 
Fig. 3. Induction of in vitro apoptosis by EGFR-TKIs in human melanoma cell lines (flow 
cytometry). Comparing gefitinib (A), PD153035 (B) and pelitinib (C), the most effective 
drug was irreversible inhibitor pelitinib while PD153035 had the lowest capacity to induce 
apoptosis (3 parallel samples, data are mean ± SD). 
Fig. 4. Effects of gefitinib (A) and pelitinib (B) pre-treatment on the in vitro migration of 
human melanoma cell lines. The inhibition of EGFR reduced migratory capacity of 
melanoma cells expressing mutant BRAF, while wild-type BRAF-expressing cells were 
unaffected. Vemurafenib-treated cells (C) served as reference. (*p<0.05 compared to solvent 
control; **no viable cells after pre-treatment, migration assay was not performed; 6 parallel 
samples, data are mean ± SD). 
Fig. 5. Effects of EGFR-TKI treatment on in vivo liver colonization of human melanoma 
cells. Pelitinib (irreversible TKI) inhibited colonization of HT168-M1 (A). Gefitinib 
(reversible TKI) inhibited WM983B, while the inhibitory effect of vemurafenib was as 
explicit as significant additional effect has not presented, only tendency has appeared (B). The 
inhibitory effect of ZD1839/gefitinib was confirmed by immunohistological examination of 
the primary WM983B xenograft tumors: compared to solvent control (C) gefitinib-treated 
tumors (D) showed lower positivity to antibody against ribosomal phospho-S6 protein. 
(*p<0.05 compared to solvent control; 10 animals per group, data are mean ± SD). 
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Table 1. Effect of EGFR-TKIs on the in vitro proliferation of human melanoma cell 
lines with different molecular background and A431 as positive control (50% 
inhibitory concentrations in μM, 5 parallel samples). The most effective drug was 
pelitinib, while all melanoma cell lines showed resistance against erlotinib. Asterisks 
indicate synergistic inhibitory effect of 5 μM vemurafenib with gefitinib in cells 
harboring V600E-mutant BRAF (NA: not available). 
 
A) Serum-free media 
   gefitinib 
(ZD1839) 
gefitinib + 
vemurafenib 
(PLX4032) 
 erlotinib 
(OSI-774) 
pelitinib  
(EKB-569) 
PD153035 
A431 0.33 NA 0.05 0.22 0.4 
M24met 
(NRAS – Q61R) 
17.2 >25 >100 2 ~100 
MEWO 
(wt NRAS-NRAF) 
>25 >25 >100 0.64 >100 
A2058 
(BRAF – V600E) 
4.72 2.15* >100 1 3.3 
HT168-M1 
(BRAF – V600E) 
1.1 1.085 >100 2.16 3.6 
HT199 
(BRAF – V600E) 
0.979 0.507* >100 0.27 8.05 
WM983B 
(BRAF – V600E) 
0.25 0.078* >100 0.38 1.93 
 
B) Media contained 2.5% of serum 
   gefitinib 
(ZD1839) 
gefitinib + 
vemurafenib 
(PLX4032) 
 erlotinib 
(OSI-774) 
pelitinib  
(EKB-569) 
PD153035 
A431 0.01 NA 0.01 0.43 0.05 
M24met 
(NRAS – Q61R) 
>25 >25 >100 0.94 >100 
MEWO 
(wt NRAS-NRAF) 
>25 >25 >100 0.127 >100 
A2058 
(BRAF – V600E) 
5.361 4.543* >100 1.1 8.51 
HT168-M1 3.87 1.213* >100 1.08 15 
Table 1 Click here to download Table Table1.doc 
(BRAF – V600E) 
HT199 
(BRAF – V600E) 
9.989 0.199* >100 1.02 30.23 
WM983B 
(BRAF – V600E) 
3.553 1.888* >100 0.22 4.51 
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